Analyst Price Targets — PMVP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 13, 2026 11:48 am | — | Oppenheimer | $5.00 | $1.42 | TheFly | PMV Pharmaceuticals price target lowered to $5 from $6 at Oppenheimer |
| November 8, 2024 11:04 am | Jeff Jones | Oppenheimer | $6.00 | $1.75 | StreetInsider | Oppenheimer Upgrades PMV Pharmaceuticals Inc. (PMVP) to Outperform |
| April 11, 2024 7:46 pm | Kambiz Yazdi | Jefferies | $5.00 | $1.58 | TheFly | PMV Pharmaceuticals initiated with a Buy at Jefferies |
| November 17, 2022 6:10 am | — | H.C. Wainwright | $36.00 | $10.29 | Benzinga | HC Wainwright & Co. Maintains Buy on PMV Pharma, Lowers Price Target to $36 |
| June 9, 2022 8:01 am | — | Oppenheimer | $33.00 | $10.24 | Benzinga | Oppenheimer Maintains Outperform on PMV Pharma, Raises Price Target to $33 |
| May 24, 2022 10:18 am | — | Goldman Sachs | $25.00 | $14.09 | Benzinga | Goldman Sachs Maintains Buy on PMV Pharma, Lowers Price Target to $25 |
Latest News for PMVP
PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PMV Pharmaceuticals (PMVP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PMVP.
U.S. House Trading
No House trades found for PMVP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.